Sanofi (SNY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.4%. By the end of trading, Sanofi rose $0.74 (1.4%) to $52.54 on light volume. Throughout the day, 853,179 shares of Sanofi exchanged hands as compared to its average daily volume of 1,704,300 shares. The stock ranged in a price between $52.18-$52.56 after having opened the day at $52.40 as compared to the previous trading day's close of $51.80. Other companies within the Drugs industry that increased today were: Agios Pharmaceuticals ( AGIO), up 26.2%, Sangamo BioSciences ( SGMO), up 17.1%, Karyopharm Therapeutics ( KPTI), up 13.9% and La Jolla Pharmaceutical ( LJPC), up 12.7%.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.5 billion and is part of the health care sector. Shares are down 3.1% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Zogenix ( ZGNX), down 14.5%, Cardiome Pharma Corporation ( CRME), down 11.7%, Kamada ( KMDA), down 11.3% and AVANIR Pharmaceuticals ( AVNR), down 11.0% , were all laggards within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings